UB Paderborn / Katalog / Suche / in CDI

Clostridium difficile Glucosyltransferase Toxin B-essential Amino Acids for Substrate Binding

The Journal of biological chemistry, 2007-11, Vol.282 (48), p.35222-35231

2007

Link zum Volltext

Verfügbarkeit prüfen

Auto-catalytic Cleavage of Clostridium difficile Toxins A and B Depends on Cysteine Protease Activity

The Journal of biological chemistry, 2007-08, Vol.282 (35), p.25314-25321

2007

Link zum Volltext

Verfügbarkeit prüfen

Cholesterol-dependent Pore Formation of Clostridium difficile Toxin A

The Journal of biological chemistry, 2006-04, Vol.281 (16), p.10808-10815

2006

Link zum Volltext

Verfügbarkeit prüfen

Processing of Clostridium difficile toxins

Journal of medical microbiology, 2008-06, Vol.57 (6), p.690-696

2008

Link zum Volltext

Verfügbarkeit prüfen

Preclinical evaluation of 4-methylthiobutyl isothiocyanate on liver cancer and cancer stem cells with different p53 status

PloS one, 2013-08, Vol.8 (8), p.e70846

2013

Link zum Volltext

Verfügbarkeit prüfen

Complex Formation between the Postsynaptic Scaffolding Protein Gephyrin, Profilin, and Mena: A Possible Link to the Microfilament System

The Journal of neuroscience, 2003-09, Vol.23 (23), p.8330-8339

2003

Link zum Volltext

Verfügbarkeit prüfen

Autocatalytic Processing of Clostridium difficile Toxin B

The Journal of biological chemistry, 2009-02, Vol.284 (6), p.3389-3395

2009

Link zum Volltext

Verfügbarkeit prüfen

Exchange of a Single Amino Acid Switches the Substrate Properties of RhoA and RhoD toward Glucosylating and Transglutaminating Toxins

The Journal of biological chemistry, 2006-07, Vol.281 (28), p.19527-19535

2006

Link zum Volltext

Verfügbarkeit prüfen

Human α-Defensins Inhibit Clostridium difficile Toxin B

Gastroenterology (New York, N.Y. 1943), 2008-06, Vol.134 (7), p.2049-2058

2008

Link zum Volltext

Verfügbarkeit prüfen

Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function

Glycobiology (Oxford), 2007-04, Vol.17 (4), p.15R-22R

2007

Link zum Volltext

Verfügbarkeit prüfen

Change of the Donor Substrate Specificity of Clostridium difficile Toxin B by Site-directed Mutagenesis

The Journal of biological chemistry, 2005-11, Vol.280 (45), p.37833-37838

2005

Link zum Volltext

Verfügbarkeit prüfen

Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance

European journal of cancer (1990), 2011-05, Vol.47 (8), p.1231-1243

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-044: A 384-well in vitro PDX culture platform for compound screening and PDX model selection

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.LB-044-LB-044

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-036: Targeting the WNT-pathway in 3D-cultures of pancreatic cancer biopsies

Cancer research (Chicago, Ill.), 2018, Vol.78 (13_Supplement), p.LB-036-LB-036

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4644: Patient-derived 3D tumor cultures for clinical diagnostics and pre-clinical drug development

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4644-4644

2018

Link zum Volltext

Verfügbarkeit prüfen

Autocatalytic Processing of Clostridium difficile Toxin B: BINDING OF INOSITOL HEXAKISPHOSPHATE

The Journal of biological chemistry, 2009-02, Vol.284 (6), p.3389-3395

2009

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-A18: Targeting the WNT-pathway in 3D-cultured in vitro PDX models for pancreas cancer

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.LB-A18-LB-A18

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5770: in vitro PDX models: 3D cultured patient-derived tumors for compound evaluation

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5770-5770

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract B70: High-throughput analysis of 3D tumor colony formation of primary cell suspensions derived from xenografts to identify efficacy of anti-tumor agents in single agent or combination therapy

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.B70-B70

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract B111: Molecular and chemosensitivity profiling of melanoma cell lines with acquired resistance to BRAF inhibitor Vemurafenib

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.B111-B111

2013

Link zum Volltext

Verfügbarkeit prüfen

In vitro cytotoxicity of cyclodextrin-bonded birch bark extract

Planta medica, 2012-06, Vol.78 (9), p.881

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3381: Overcoming resistance to BRAF inhibitors in colon cancer and melanoma cell lines

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3381-3381

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3699: Molecular profiling of BRAFi-resistance in melanoma cancer models using high-throughput sequencing in patient-derived xenografts

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.3699-3699

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract C25: The use of a patient derived tumor xenograft collection to assess different Met and HGF detection methods and their predictive values for therapy response

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.C25-C25

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract C30: A KRAS pathway activation index predicting response to MEK inhibitors in patient-derived tumor xenografts

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.C30-C30

2013

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Clostridium difficile Glucosyltransferase Toxin B-essential Amino Acids for Substrate Binding

Auto-catalytic Cleavage of Clostridium difficile Toxins A and B Depends on Cysteine Protease Activity

Cholesterol-dependent Pore Formation of Clostridium difficile Toxin A

Processing of Clostridium difficile toxins

Preclinical evaluation of 4-methylthiobutyl isothiocyanate on liver cancer and cancer stem cells with different p53 status

Complex Formation between the Postsynaptic Scaffolding Protein Gephyrin, Profilin, and Mena: A Possible Link to the Microfilament System

Autocatalytic Processing of Clostridium difficile Toxin B

Exchange of a Single Amino Acid Switches the Substrate Properties of RhoA and RhoD toward Glucosylating and Transglutaminating Toxins

Human α-Defensins Inhibit Clostridium difficile Toxin B

Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function

Change of the Donor Substrate Specificity of Clostridium difficile Toxin B by Site-directed Mutagenesis

Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance

Abstract LB-044: A 384-well in vitro PDX culture platform for compound screening and PDX model selection

Abstract LB-036: Targeting the WNT-pathway in 3D-cultures of pancreatic cancer biopsies

Abstract 4644: Patient-derived 3D tumor cultures for clinical diagnostics and pre-clinical drug development

Autocatalytic Processing of Clostridium difficile Toxin B: BINDING OF INOSITOL HEXAKISPHOSPHATE

Abstract LB-A18: Targeting the WNT-pathway in 3D-cultured in vitro PDX models for pancreas cancer

Abstract 5770: in vitro PDX models: 3D cultured patient-derived tumors for compound evaluation

Abstract B70: High-throughput analysis of 3D tumor colony formation of primary cell suspensions derived from xenografts to identify efficacy of anti-tumor agents in single agent or combination therapy

Abstract B111: Molecular and chemosensitivity profiling of melanoma cell lines with acquired resistance to BRAF inhibitor Vemurafenib

In vitro cytotoxicity of cyclodextrin-bonded birch bark extract

Abstract 3381: Overcoming resistance to BRAF inhibitors in colon cancer and melanoma cell lines

Abstract 3699: Molecular profiling of BRAFi-resistance in melanoma cancer models using high-throughput sequencing in patient-derived xenografts

Abstract C25: The use of a patient derived tumor xenograft collection to assess different Met and HGF detection methods and their predictive values for therapy response

Abstract C30: A KRAS pathway activation index predicting response to MEK inhibitors in patient-derived tumor xenografts

Suchergebnisse filtern